201 related articles for article (PubMed ID: 9830501)
1. Crucial suppressive role of renal kallikrein-kinin system in development of salt-sensitive hypertension.
Katori M; Majima M; Hayashi I
Biol Res; 1998; 31(3):143-9. PubMed ID: 9830501
[TBL] [Abstract][Full Text] [Related]
2. Role of the renal kallikrein-kinin system in the development of salt-sensitive hypertension.
Katori M; Majima M; Hayashi I; Fujita T; Yamanaka M
Biol Chem; 2001 Jan; 382(1):61-4. PubMed ID: 11258674
[TBL] [Abstract][Full Text] [Related]
3. Role of the renal kallikrein-kinin system in the development of hypertension.
Katori M; Majima M
Immunopharmacology; 1997 Jun; 36(2-3):237-42. PubMed ID: 9228552
[TBL] [Abstract][Full Text] [Related]
4. Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Nakajima S; Majima M; Ito H; Hayashi I; Yajima Y; Katori M
Int J Tissue React; 1998; 20(2):45-56. PubMed ID: 9638501
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of kinin degradation on the luminal side of renal tubules reduces high blood pressure in deoxycorticosterone acetate salt-treated rats.
Nakajima S; Ito H; Hayashi I; Kuribayashi Y; Okumura T; Yajima Y; Katori M; Majima M
Clin Exp Pharmacol Physiol; 2000; 27(1-2):80-7. PubMed ID: 10696533
[TBL] [Abstract][Full Text] [Related]
6. Essential role of kallikrein-kinin system in suppression of blood pressure rise during the developmental stage of hypertension induced by deoxycorticosterone acetate-salt in rats.
Katori M; Majima M; Mohsin SS; Hanazuka M; Mizogami S; Oh-ishi S
Agents Actions Suppl; 1992; 38 ( Pt 3)():235-42. PubMed ID: 1281379
[TBL] [Abstract][Full Text] [Related]
7. Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats.
Majima M; Ikeda Y; Kuribayashi Y; Mizogami S; Katori M; Aoyagi T
Eur J Pharmacol; 1995 Sep; 284(1-2):1-11. PubMed ID: 8549611
[TBL] [Abstract][Full Text] [Related]
8. An ATP-sensitive potassium channel blocker suppresses sodium-induced hypertension through increased secretion of urinary kallikrein.
Kamata Y; Fujita T; Kato T; Hayashi I; Kurosaka M; Katori M; Fujita Y; Majima M
Hypertens Res; 2009 Mar; 32(3):220-6. PubMed ID: 19262486
[TBL] [Abstract][Full Text] [Related]
9. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth.
Ikeda Y; Hayashi I; Kamoshita E; Yamazaki A; Endo H; Ishihara K; Yamashina S; Tsutsumi Y; Matsubara H; Majima M
Cancer Res; 2004 Aug; 64(15):5178-85. PubMed ID: 15289322
[TBL] [Abstract][Full Text] [Related]
10. Facilitation of renal kallikrein-kinin system prevents the development of hypertension by inhibition of sodium retention.
Majima M; Hayashi I; Fujita T; Ito H; Nakajima S; Katori M
Immunopharmacology; 1999 Oct; 44(1-2):145-52. PubMed ID: 10604538
[TBL] [Abstract][Full Text] [Related]
11. Cellular and functional aspects of the renal kallikrein system in health and disease.
Vio CP; Olavarría V; González C; Nazal L; Córdova M; Balestrini C
Biol Res; 1998; 31(3):305-22. PubMed ID: 9830518
[TBL] [Abstract][Full Text] [Related]
12. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship.
Katori M; Majima M
Jpn J Pharmacol; 1996 Feb; 70(2):95-128. PubMed ID: 8866749
[TBL] [Abstract][Full Text] [Related]
13. The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension.
Katori M; Majima M
Crit Rev Clin Lab Sci; 2003 Feb; 40(1):43-115. PubMed ID: 12627748
[TBL] [Abstract][Full Text] [Related]
14. Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension.
Katori M; Majima M
Prog Drug Res; 2014; 69():59-109. PubMed ID: 25130040
[TBL] [Abstract][Full Text] [Related]
15. A missing link between a high salt intake and blood pressure increase.
Katori M; Majima M
J Pharmacol Sci; 2006; 100(5):370-90. PubMed ID: 16651701
[TBL] [Abstract][Full Text] [Related]
16. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
Ito H; Majima M; Nakajima S; Hayashi I; Katori M; Izumi T
Br J Pharmacol; 1999 Feb; 126(3):613-20. PubMed ID: 10188971
[TBL] [Abstract][Full Text] [Related]
17. A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.
Katori M; Majima M
Pharmaceuticals (Basel); 2010 Jan; 3(1):59-109. PubMed ID: 27713243
[TBL] [Abstract][Full Text] [Related]
18. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats.
Majima M; Yoshida O; Mihara H; Muto T; Mizogami S; Kuribayashi Y; Katori M; Oh-ishi S
Hypertension; 1993 Nov; 22(5):705-14. PubMed ID: 7693588
[TBL] [Abstract][Full Text] [Related]
19. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system.
Majima M; Katori M; Hanazuka M; Mizogami S; Nakano T; Nakao Y; Mikami R; Uryu H; Okamura R; Mohsin SS
Hypertension; 1991 Jun; 17(6 Pt 1):806-13. PubMed ID: 1710605
[TBL] [Abstract][Full Text] [Related]
20. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
